Dr Reddys Laboratories Ltd

Mid Cap

Healthcare Sector

reflects a positive outlook for the share price

reflects a neutral outlook for the share price

reflects a negative outlook for the share price

The analysts information is for reference only and does not\n  represents an investment recommendation.

Analyst recommendation reflect the views of analysts who follow and write research reports.

Company Information is an introduction to the company’s business that details what it sell, how it was founded, what their mission is, how they manufacture or source their products, and why they serve customers.

Dr Reddy's Laboratories reported a 14% decline in net profit to ₹1,210 crore for Q3 FY26, but revenue grew 4.4%. Strong performance in India helped offset losses from North America. The company is set to launch semaglutide in India in March.

Dr Reddy's Q3 Results Beat Estimates Despite Profit Drop - 21 Jan, 2026

Dr Reddy’s Laboratories has launched the first generic version of Pataday Extra Strength eye drops in the US, enhancing its OTC eye-care offerings. The product aims to provide temporary relief from itchy eyes due to allergens.

Dr Reddy’s Launches Generic Eye Drops in US - 14 Jan, 2026

Citi has reiterated a sell rating on Dr. Reddy's Laboratories, projecting a 28% downside due to competitive challenges from Novo Nordisk's semaglutide strategy, estimating revenues significantly below market expectations.

Citi Issues Sell Rating on Dr. Reddy's Stock - 08 Jan, 2026

Dr Reddy's Laboratories launched Hevaxin, the first hepatitis E vaccine approved in India, while also reporting a significant decline in US sales by 28% year-on-year.

Dr Reddy's Launches Vaccine Amid Sales Decline - 06 Jan, 2026

Dr Reddys Laboratories divested its stake in Venezuela in 2024 and received court approval to export a drug to patent-free regions, pending Canadian regulatory approval.

Dr Reddys Updates on Export and Divestment - 05 Jan, 2026

Dr Reddy's Laboratories faces regulatory challenges as JPMorgan reiterates an Underweight rating and sets a target price of Rs 1,170, following a Complete Response Letter from the USFDA for its biosimilar Denosumab.

JPMorgan Flags Regulatory Setback for Dr Reddy's - 02 Jan, 2026

Dr Reddy's Laboratories received a Complete Response Letter from the USFDA for its AVT03 biosimilar application. Additionally, the Centre banned Nimesulide formulations, affecting the company's market.

Dr Reddy's Faces Regulatory Setbacks and Market Changes - 31 Dec, 2025

Chairman Satish Reddy of Dr. Reddy's Laboratories emphasizes the importance of accessible risk capital for India's transition to a pharmaceutical innovation hub, projecting a positive outlook for 2026.

Dr. Reddy's Chairman Highlights Innovation for Growth - 28 Dec, 2025

Dr Reddy’s Laboratories has not received approval for its generic semaglutide in Canada, as it fails to meet Health Canada's regulatory standards, delaying potential market entry.

Dr Reddy's Semaglutide Faces Regulatory Setback in Canada - 24 Dec, 2025

Price to Earnings Ratio or Price to Earnings Multiple is the ratio of the share price of a stock to its earnings per share (EPS). It provides an indication of whether a stock at its current market price is expensive or cheap.

The price/earnings-to-growth ratio, or the PEG ratio, is a metric that helps investors value a stock by taking into account a company's market price, its earnings, and its future growth prospects.

Enterprise value (EV) is the total value of a company, defined in terms of its financing. It includes both the current share price (market capitalization) and the cost to pay off debt (net debt, or debt minus cash).

Alpha measures the amount that the investment has returned in comparison to the market index or other broad benchmark that it is compared against.

Beta measures a stock's volatility, the degree to which its price fluctuates in relation to the overall stock market. In other words, it gives a sense of the stock's risk compared to that of the greater market.

Dividend yield measures the quantum of earnings by way of total dividends that investors make by investing in that company.

The debt-to-total-assets ratio shows how much of a business is owned by creditors (people it has borrowed money from) compared with how much of the company's assets are owned by shareholders.

Operating cash flow (OCF) is a measure of the amount of cash generated by a company's normal business operations. Operating cash flow indicates whether a company can generate sufficient positive cash flow to maintain and grow its operations.

This widget shows the information about the stock's peers in consideration along with the different data for those peers so that the user can compare the stock with the other similar stock and invest accordingly.

Promoter holding is the amount of share of the company that is owned by the promoters. The promoters are the company's founders, who hold a majority stake in the company's capital.

A foreign institutional investor (FII) is an investor or investment fund investing in a country outside of the one in which it is registered or headquartered.

A mutual fund is a pool of money managed by a professional Fund Manager. It is a trust that collects money from a number of investors who share a common investment objective and invests the same in equities, bonds, money market instruments, and other securities.

Retail investors execute their trades through traditional or online brokerage firms or other types of investment accounts. Retail investors purchase securities for their own personal accounts and often trade in dramatically smaller amounts as compared to institutional investors.

This widget shows the bifurcation of stocks based on the percentage of stake with the different types of shareholders.

This widget will help value the stock based on the Price to Earning ratio of the stock and compare the valuation with the industry value and other similar stocks. It even shows the timeline of the valuation of the stock and its highest and lowest valuation over time.
A Time Series data is provided which compares the historical stock PE with Industry PE over the period of 5 years.

Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.

Revenue is up for the last 2 quarters, 8.86K Cr → 9.15K Cr (in ₹), with an average increase of 3.2% per quarter

This section gives you an insight into how the revenue of the company has moved for the last few quarters.

Revenue Rich

Promoters holdings remained unchanged at 26.64% of holdings in Sep 2025 quarter

This section gives you an insight into how the Promoter Holding has changed for the stock over the last few quarters.

Promoter Holding Unchanged

Retail Investor have decreased holdings from 10.00% to 9.61% in Sep 2025 quarter

This section gives you an insight into how the Retail Investors Holding has changed for the stock over last few quarters.

Retail Holding Down

Mutual Funds have decreased holdings from 13.61% to 13.31% in Sep 2025 quarter

This section gives you an insight into how the Mutual Funds Holding has changed for the stock over last few quarters.

MF Holding Down

Netprofit is down for the last 3 quarters, 1.59K Cr → 1.34K Cr (in ₹), with an average decrease of 8.0% per quarter

This section gives you an insight into how the profit for the company has been for the last few quarters.

Profit Down

Foreign Institutions have decreased holdings from 25.32% to 24.69% in Sep 2025 quarter

This section gives you an insight into how the FII Holding has changed for the stock over last few quarters.

FII Holding Down

In the last 7 days, DRREDDY stock has moved down by -1.7%

This section gives you an insight into the price movement of the stock for the last few quarters.

Price Dip

S&P BSE 100 ESG

S&P BSE Largecap

S&P BSE 250 LargeMidCap

Nifty50 Value 20

BSE 200

BSE 500

BSE MFG

BSE Healthcare

Nifty LargeMidcap 250

Nifty100 Eq Weig

S&P BSE 100 LargeCap TMC

S&P BSE Dividend Stability

NIFTY 50

BSE 100

Nifty100 Quality

NIFTY 100

S&P BSE SENSEX 50

Nifty Healthcare

Nifty 200

NIFTY PHARMA

S&P BSE Low Volatility

Nifty100 Low Volatility 30

Nifty 500

Parag Parikh Flexi Cap Direct Growth

ICICI Prudential Value Fund Direct Plan Growth

Nippon India Large Cap Fund - Direct Plan - Growth Plan

ICICI Prudential Pharma Healthcare and Diagnostics (P.H.D) Fund Direct Growth

Nippon India Pharma Fund - Direct Plan - Growth Plan

Dr. Reddy's Laboratories reports Q3 net profit of Rs 1,209 crore, with revenue of Rs 8,753 crore exceeding estimates.

Dr Reddys Laboratories Ltd’s net profit jumped 7.28% since last year same period to ₹1,347.10Cr in the Q2 2025-2026. On a quarterly growth basis, Dr Reddys Laboratories Ltd has generated -5.01% fall in its net profits since last 3-months.

Dr Reddys Laboratories Ltd Earnings Results

In the quarter ending March 2025, Dr Reddys Laboratories Ltd has declared dividend of ₹8.00 per share on 09 May 2025 - translating a dividend yield of 0.69%.

Name	Value	Action
MACD level (12,26)	-0.7	Bearish
CCI (20)	414.75	Bearish
RSI (14)	32.66	Neutral
Momentum (10)	-4.2	Bearish
ADI (14)	18.29	Neutral
Ultimate Oscillator (7,14,28)	19.47	Bearish

Name	Value	Action
SMA (20)	1156.73	Bearish
EMA (20)	1156.71	Bearish
VWMA (20)	1156.65	Bearish
SMA (50)	1158.69	Bearish
EMA (50)	1157.49	Bearish
SMA (200)	1158.93	Bearish
EMA (200)	1158.89	Bearish
KAMA (200)	1158.51	Bearish
DEMA (200)	1155.84	Bearish

Dr Reddys Laboratories Ltd (DRREDDY)

Summary

Overall

Oscillators

Moving Averages